Multivariate Analysis of Several Molecular Markers and Clinicopathological Features in Postoperative Prognosis of Hepatocellular Carcinoma

Anatomical Record

Volumn 295, Issue 3, 2012, Pages 423-431

  Zuo, Qiang ^a   Huang, Hui ^b   Shi, Min ^a   Zhang, Futing ^a   Sun, Jiping ^a   Bin, Jianping ^a   Liao, Yulin ^a   Liao, Wangjun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

H ras; Hepatocellular carcinoma; K ras; PIK3CA; Prognosis; Survival analysis; XB130

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN XB130; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONCOGENE H RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PYROSEQUENCING; RETROSPECTIVE STUDY; RISK FACTOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENES, RAS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; RISK FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84857056401     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21531     Document Type: Article

References (45)

1. Aggarwal C, Somaiah N, Simon GR. 2010. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw 8: 822-832.
2. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R, Rodes J. 1990. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 12: 753-760.
3. Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. 1999. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med 123: 524-528.
4. Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. 2010. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol 36: 657-662.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
6. Cheng HY, Wang X, Chen D, Xu AM, Jia YC. 2005. The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. World J Gastroenterol 11: 3644-3646.
7. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. 1999. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 31: 133-141.
8. Conway C, Beswick S, Elliott F, Chang YM, Randerson-Moor J, Harland M, Affleck P, Marsden J, Sanders DS, Boon A, Knowles MA, Bishop DT, Newton-Bishop JA. 2010. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer 49: 425-438.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
10. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. 2008. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
12. Friedrichs K, Gluba S, Eidtmann H, Jonat W. 1993. Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647.
13. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. 2000. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60: 6750-6756.
14. Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y. 1992. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 69: 72-77.
15. He Y, Van't Veer LJ, Mikolajewska-Hanclich I, van Velthuysen ML, Zeestraten EC, Nagtegaal ID, van de Velde CJ, Marijnen CA. 2009. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 15: 6956-6962.
16. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE. 2009. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 28: 3022-3032.
17. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. 2003. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3: 19.
18. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, Aragaki J, Matsumura M, Kawabe T, Omata M. 2003. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 63: 8132-8137.
19. Imai Y, Oda H, Arai M, Shimizu S, Nakatsuru Y, Inoue T, Ishikawa T. 1996. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn J Cancer Res 87: 1056-1062.
20. Kang S, Bader AG, Vogt PK. 2005. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802-807.
21. Lam CM, Yong JL, Chan AO, Ng KK, Poon RT, Liu CL, Lo CM, Fan ST. 2005. Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related? J Clin Gastroenterol 39: 533-539.
22. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. 2005. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24: 1477-1480.
23. Lodyga M, Bai XH, Kapus A, Liu M. 2010. Adaptor protein XB130 is a Rac-controlled component of lamellipodia that regulates cell motility and invasion. J Cell Sci 123: 4156-4169.
24. Lodyga M, De Falco V, Bai XH, Kapus A, Melillo RM, Santoro M, Liu M. 2009. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene 28: 937-949.
25. Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM. 2009. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 51: 725-733.
26. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. 2010. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474.
27. Samuels Y, Diaz LA, Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. 2005. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
28. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
29. Sasaki A, Iwashita Y, Shibata K, Ohta M, Kitano S, Mori M. 2006. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 32: 773-779.
30. Stuart KE, Anand AJ, Jenkins RL. 1996. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 77: 2217-2222.
31. Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, Ohta M, Ikenoue T, Tateishi K, Obi S, Kawabe T, Yokosuka O, Omata M. 2006. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 25: 2950-2952.
32. Tang ZY. 2000. Hepatocellular carcinoma. J Gastroenterol Hepatol 15 ( Suppl): G1-G7.
33. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. 2000. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 31: 302-308.
34. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. 2003. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706-712.
35. Toyoda H, Kumada T, Osaki Y, Oka H, Kudo M. 2007. Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res 37 ( Suppl 2): S166-S171.
36. Tuveson DA, Weber BL, Herlyn M. 2003. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4: 95-98.
37. Uenishi T, Hirohashi K, Shuto T, Kubo S, Tanaka H, Sakata C, Ikebe T, Kinoshita H. 2000. The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. Surg Today 30: 892-895.
38. Wang Q, Lin ZY, Feng XL. 2001. Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection. World J Gastroenterol 7: 335-339.
39. Weihrauch M, Benicke M, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. 2001. Frequent k-ras-2 mutations and p16(INK4A)methylation in hepatocellular carcinomas in workers exposed to vinyl chloride. Br J Cancer 84: 982-989.
40. Xu J, Bai XH, Lodyga M, Han B, Xiao H, Keshavjee S, Hu J, Zhang H, Yang BB, Liu M. 2007. XB130, a novel adaptor protein for signal transduction. J Biol Chem 282: 16401-16412.
41. Xu RF, Sun JP, Zhang SR, Zhu GS, Li LB, Liao YL, Xie JM, Liao WJ. 2010. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother 65: 22-26.
42. Ye C, Kiriyama K, Mistuoka C, Kannagi R, Ito K, Watanabe T, Kondo K, Akiyama S, Takagi H. 1995. Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer 61: 455-460.
43. Zhang Z, Wu M, Chen H, Yang J, Yang G, Shen F, He J. 2002. The effect of postoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 40: 329-331.
44. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A. 2010. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 127: 367-380.
45. Zuo Q, Shi M, Li L, Chen J, Luo R. 2010. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. Biomed Pharmacother 64: 550-558.